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Background: The aim of this study was to investigate how differences in expression of HER2 between primary
gastric cancers (PGCs) and their corresponding metastatic lymph nodes (LMNs) might affect its potential as a
prognostic indicator in treatments including anti-HER2 agents.
Methods: The analysis was conducted in 102 patients who underwent surgical resection for primary gastric cancers
(PGCs; adenocarcinoma, intestinal type) with synchronous LNMs. HER2 gene status and protein expression were
investigated by immunohistochemistry (IHC) in all patients; fluorescence in situ hybridization (FISH) was performed
in 22 patients. The correlation between HER2 gene status in PGCs and their LNMs was evaluated.
Results: Positive HER2 expression as detected by IHC + FISH was observed in 27/102 PGC samples (26.5%) and 29/102
LNM samples (28.4%). HER2 amplification status in 102 paired PGC and LNM samples as evaluated by FISH + IHC was
concordant in 92 patients (90.2%), 69 (67.6%) were unamplified and 23/102 (22.5%) were amplified at both sites, and
discordant in 10 patients (9.8%), 4 (3.9%) were positive for PGC and negative for LNM, while 6 (5.9%) were positive for
LNM and negative for PGC. The results of FISH + IHC showed very strong concordance in HER2 status between the PGC
and LNM groups (k = 0.754).
Conclusion: The high concordance between HER2 results for PGCs and their LNMs indicates that assessment of HER2
status in the primary cancer alone is a reliable basis for deciding treatment with anti-HER2 agents in patients with LNMs
from gastric adenocarcinoma.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
9365749431029643.
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A large number of studies have shown that HER2-
positivity, which is associated with poor prognosis, is de-
tected in 7% to 34% of patients with gastric cancer [1-9].
Moreover, recent advances in technology have made detec-
tion of HER2 much easier, thus increasing its potential as a
prognostic marker [10,11].
Currently, clinical trials of trastuzumab and lapatinib
are being conducted based on the findings of earlier* Correspondence: takayama.tadatoshi@nihon-u.ac.jp
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reproduction in any medium, provided the orpreclinical in vitro and in vivo studies demonstrating
that they were effective in different gastric cancer models.
Trastuzumab, a monoclonal antibody against human
epidermal growth factor receptor 2 (HER2; also known
as ERBB2), in combination with chemotherapy is con-
sidered a new standard option in patients with HER2-
positive advanced gastric or gastro-esophageal junction
cancer [12]. The efficacy of trastuzumab in metastatic
gastric cancer may be influenced by downstream de-
regulation of HER2 signaling proteins detected in the
primary tumor.
These earlier data were obtained by analyzing the cli-
nical response in gastric cancer patients with regard totd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cers (PGCs). However, metastases may have molecular
patterns which differ from those of the primary tumor,
and this might affect how accurately we can predict the
efficacy of HER2-targeted therapy. Differences in HER2
expression between primary tumors and their lymph
node metastases (LMNs) could not explain the high pro-
portion of non-responders to trastuzumab therapy in
breast cancer [13-15]. However, the level of expression
of a particular molecular marker or gene status may dif-
fer between a PGC and its corresponding metastatic
lesions, and this may affect the clinical significance of
predictive tests.
The purpose of the present study was to determine
how differences in expression of HER2 between PGCs
and their corresponding LMNs might affect its potential




Between January 1990 and December 2010, 102 patients
underwent gastrectomy for PGCs histopathologically clas-
sified as adenocarcinoma, intestinal type together with dis-
section of synchronous LNMs at the Department of
Digestive Surgery, Nihon University School of Medicine
Itabashi Hospital. The analysis was conducted in PGCs
with synchronous LNMs. Tissue specimens were obtained
from both the PGCs and their associated LNMs. All the
specimens were fixed in 4% neutral buffered formalin and
embedded in paraffin before being sent to a local pathology
facility for evaluation. This study was approved by the
Research review board, Nihon University School of Medicine,
Itabashi Hospital (No RK-100910).
Molecular analyses
All the specimens obtained were reviewed for quality
and tumor content. A single representative tumor speci-
men from each patient containing at least 70% neoplastic
cells was selected for immunohistochemical, cytogenetic,
and molecular analyses. The tumor blocks were cut
into 3-μm thick sections for analysis by both fluores-
cence in situ hybridization (FISH) and immunohisto-
chemistry (ICH).
Assessment of HER2 status by IHC
The tumors were centrally tested by ICH for HER2 status
(HercepTest; Dako, Kyoto, Japan). HER2 immunoreactivity
was evaluated by an experienced pathologist according to
the scoring system of Hofmann et al. [16]. Samples exhibit-
ing strong, complete, basolateral or lateral membranous
reactivity (3+) in ≥10% of the cells were scored as posi-
tive. Samples with no reactivity or membranous re-
activity in <10% of the cells, or with only faint or barelyperceptible membranous reactivity (1+) in ≥10% of the
tumor cells (cells showing reactivity in only one area of
their membrane) were considered negative. Samples
showing weak-to-moderate, complete, basolateral or la-
teral membranous reactivity (+2) in ≥10% of the tumor
cells were scored as equivocal. Patients were eligible if
their tumor samples were scored as 2+ on IHC, or if the
samples were FISH-positive.
Assessment of HER2 status by FISH
HER2 amplification was assessed in histological samples
of both PGCs and LNMs by using a Spectrum Green
fluorophore-labeled α-satellite DNA probe for chromo-
some 17 (CEP17) and a Spectrum Orange fluorophore-
labeled DNA probe for the HER2 gene locus (VysisPath
VysionHER2 DNA Probe Kit; Vysis-Abbott, Japan).
Slides were hybridized using the Hybrite denaturation/
hybridization system for FISH (Vysis). Chromosome 17
polysomy was defined as ≥3 CEP17 signals on average per
cell. Amplification was defined as an HER2/CEP17 ratio
of ≥2, or when an HER2 signal cluster was observed.
Statistical analysis
Concordance between HER2 status in the primary
tumor and its related metastatic sites was evaluated
using Cohen’s κ-test, which is appropriate for assessing
concordance between two categorical measurements in
the same individual. A κ-value of between 0.61 and 0.8 was
assumed to indicate a very strong agreement. A P value of
less than 0.05 was considered to indicate statistical signifi-
cance. The SAS software package for Windows, version
8.02 (SAS Institute Inc., Cary, NC, USA), and Microsoft
Excel 2003 (Microsoft Co., Ltd., Japan) were used for the
statistical analysis and data calculation.
Results
Patient characteristics are summarized in Table 1. The 102
patients included 82 men (80.4%) and 20 women (19.6%).
The median age at the time of diagnosis was 68 years (ran-
ging from 29 to 86 years). Upper gastric cancer was present
in 27 patients and middle and lower gastric cancer in 75.
All patients were classified as having adenocarcinoma, in-
testinal type tumors. The median number of metastatic
lymph nodes was 2 greater in the male group than that
in the female group (4[1-100] vs. 2[1-10]respectively;
P = 0.013). No statistically significant difference was ob-
served in any clinical feature between males and females
apart from in number of metastatic sites. The HER2
gene copy number was evaluated by IHC in 102 con-
secutive primary gastric adenocarcinoma specimens and
their corresponding metastatic lesions and by FISH in
22. All 102 PGC and LNM specimens were adequate
for IHC evaluation of HER2 status. Of the 23 PGC speci-
mens and 23 LNM specimens selected for FISH evaluation,
Table 1 Patient demographics and tumor characteristics
Total (%) Male (%) Female (%)





Median [Range] 68 [29-86] 68 [29-84] 72[29-86]
29-49 18 (17.6) 16 (19.5) 2 (10.0)
50-79 73 (71.6) 59 (57.8) 14 (70.0)
79-86 11 (10.8) 7 (8.5) 4 (20.0)
Location 0.868
Upper 27 (26.5) 22 (26.8) 5 (33.3)
Middle + Lower 75 (73.5) 60 (73.2) 15 (66.6)
Operation method 0.454
Partial 64 (62.7) 50 (61.0) 14 (70.0)
Total 38 (37.3) 32 (39.0) 6 (30.0)
Curability 0.147
No residual tumors 87 (85.3) 72 (87.8) 15 (75.0)
Definite residual tumor 15 (14.7) 10 (12,2) 5 (25.0)
Clinical stage (TNM) 0.563
Stage I-III 82 (80.4) 65 (79.3) 17 (85.0)
Stage IV 20 (19.6) 17 (20.7) 3 (15.0)
Histological stage (TNM) 0.936
Stage II-III 86 (84.3) 69 (84.2) 17 (85.0)
Stage IV 16 (15.7) 13 (15.8) 3 (15.0)
Histological type
Intestinal 141 (100) 82 (100) 20 (100)
Diffuse 0 (0) 0 (0) 0 (0)
No of LN metastases 0.013
Median [Range] 4 [1-100] 4 [1-100] 2 [1-10]





Negative (0, 1+) 62 60.8 6
Equivocal (2+) 2 2.0 2
Positive (3+) 4 3.9 4
Total 68 66.6 12
k = 0.629.
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tissue fixation.Assessment of HER2 status by IHC
HER2 expression as detected by IHC was positive or
equivocal in 32 out of 102 PGC specimens (31.4%) and
34 out of 102 LNM specimens (33.3%). Overall, the general
pattern of HER2 protein expression in each PGC was the
same as in its corresponding LNMs (Table 2). HER2 ampli-
fication status was evaluable in 102 paired PGC and LNM
specimens: 26 (25.5%) were amplified and 62 (60.8%) were
unamplified at both sites. There were 6 discordant cases
(5.9%), where HER2 status was positive or equivocal in
PGC but negative in the LNM, and 8 discordant cases
(7.8%), where HER2 status was positive or equivocal in the
LNM but negative in the PGC. The results of IHC showed
strong concordance in HER2 status between the PGC and
LNM groups (k = 0.629).Assessment of HER2 status by FISH + IHC
Of the 22 suitable PGC and LNM samples showing a re-
sult of 2+ by IHC or a discordance in ICH results be-
tween PGC and LNM, 12 of the PGC specimens (54.5%)
showed positive HER2 expression, while 11 of the LNM
samples (50.0%) showed positive (+2) HER2 expression as
detected by FISH. Of the 102 PGC samples, 27 (26.5%)
showed positive HER2 expression as detected by FISH +
IHC, while 29 of 102 LNM samples (28.4%) showed posi-
tive HER2 expression. Overall, the general pattern of HER2
protein expression in PGC as assessed by FISH + IHC
was the same as in its corresponding LNM (Table 3).
The HER2 amplification status was evaluable by FISH +
IHC in 102 paired PGC and LNM specimens: 23 (22.5%)
were amplified and 69 (67.6%) were unamplified at both
sites. There were 4 discordant cases (3.9%), where HER2
status was positive in the PGC but negative in the LNM
(Figure 1), and 6 discordant cases (5.9%), where HER2
status was positive in the LNM but negative in the PGC
(Figure 2). The results of FISH + IHC showed very strongprimary gastric carcinomas and their corresponding
LN metastatic site
al % Positive % Total %
(3+)
5.8 2 2.0 70 68.6
2.0 3 2.9 7 9.6
3.9 17 16.7 25 24.5
11.8 22 21.6 102 100
Table 3 Comparison of HER2 status as assessed by IHC
and FISH in 102 primary gastric carcinomas and their
corresponding lymph node metastases
LN metastatic site
Negative % Positive % Total %
Primary tumor
Negative 69 67.6 6 5.9 75 73.5
Positive 4 3.9 23 22.5 27 26.5
Total 73 71.6 29 28.4 102 100
k = 0.754.
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groups (k = 0.754).
Discussion
In the ToGA trial, the first phase III study of trastu-
zumab in conjunction with standard chemotherapy,
HER2-positive patients with advanced gastric or gastro-
esophageal junction cancer were randomized to receive
5-fluorouracil/capecitabine and cisplatin, either alone or
in combination with trastuzumab. Based on the results of
that study, HER2-targeted molecular therapies acquired
high relevance in the treatment of gastric cancer [12],
indicating the importance of identifying which clinical
and/or pathological features or molecular differences
might be predictive of sensitivity or resistance to anti-
HER2 therapies.
Amplification of the HER2 gene and over-expression
of its protein in gastric cancer were first described inFigure 1 HER2 expression as detected by IHC and FISH in discordant
the PGC. (A) FISH-positive LNM sample. (B) IHC-positive LNM sample. (C) F1986 [17], since which a number of studies have con-
firmed those findings [18-20]. However, how differing
deregulation of HER2 between the primary gastric can-
cer and its metastases affects its potential as a prog-
nostic factor remains to be clarified. Axillary lymph
node metastasis is one of the most important prog-
nostic determinants in breast carcinoma. The histo-
pathologic characteristics and expression of biological
markers vary among the same histologic subtypes of
breast carcinoma. This suggests that the specific clin-
ical and histopathologic features of the primary tumor
and axillary lymph node metastases such as to a senti-
nel node might be used to tailor loco-regional and sys-
temic treatment in different clinical settings in breast
cancer [13-15].
Although molecular patterns may differ between a pri-
mary tumor and its associated metastases, patterns used
to predict response to a given agent are usually derived
from those within the primary tumor, with little attention
to those found at other sites. Only a few studies have been
published on this subject. Some studies assessed HER2 sta-
tus in gastric cancer and confirmed a high level of con-
cordance between HER2 status in the PGC and at various
metastatic sites [20-23]. However, another study reported
discordant data between HER2 status in the PGC and at
various metastatic sites [24]. However, given the low num-
ber of cases analyzed and the types of cytological analysis
used in these earlier studies, it is difficult to draw any con-
clusion with regard to HER2 status in synchronous and
metachronous metastases.cases where HER2 status was positive in the LNM but negative in
ISH-negative PGC sample. (D) IHC-negative PGC sample.
Figure 2 HER2 expression as detected by IHC and FISH in discordant cases, where HER2 status was positive in the PGC but negative in
the LNM. (A) FISH-negative LNM sample. (B) IHC-negative LNM sample. (C) FISH-positive PGC sample. (D) IHC-positive PGC sample.
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molecular patterns which differ from those in the primary
tumor is supported by our current assessment of HER2
gene status by IHC and FISH. The present results showed
only a moderate correlation between HER2 gene status in
the PGCs and that in the LNMs. Therefore, HER2 evalu-
ation by IHC and FISH performed only on the primary
tumor may not be accurate enough to select candidates for
targeted therapy. The heterogeneity of HER2 gene status in
neoplastic tissues obtained from different sites in the same
patient is confirmed by our findings in synchronous LNMs,
with a number of patients showing a difference in HER2
gene status between the primary tumor and its distant me-
tastasis: in 4 cases (3.9%) the HER2 gene status was ob-
served to be positive in the PGCs and negative in the
LNMs, while in 6 cases (5.9%), HER2 gene status was posi-
tive in the LNMs and negative in the PGCs. It is important
to note, however, that concordance between the PGCs and
LMNs was found in 92 of the 102 patients included in this
study (90.2%). This suggests that the treatment policy
could be decided based on a sample of the PGC alone in
cases where there are recurrent metastases.
Even though treatment with trastuzumab is effective,
the decision to treat with trastuzumab is currently based
on HER2 assessment in the PGC alone. However, the
present results suggest that, as much as possible, the de-
cision to treat with trastuzumab should be based on
HER2 status as assessed in metastatic lesions.
The samples obtained in this study were obtained as
far back as 1990, which means that some of them wereunsuitable for application of FISH, although IHC was
possible in all. To our knowledge, this is the first study
including a large sample of HER2-positive patients to in-
vestigate the effect of molecular differences on the po-
tential of HER2 status as a prognostic marker in PGCs
with synchronous LNMs.Conclusion
The results of this study indicate that HER2 status in the
PGC is a reliable basis for deciding whether to treat with
anti-HER2 agents in patients with LNMs. Further pro-
spective studies are needed, however, to determine the
validity of these findings. We believe that these results
may be of use in clinical practice and should be taken
into account in designing future clinical trials based on
anti-HER2 therapy.Consent
Written informed consent was obtained from the pa-
tients for publication of this report and any accompany-
ing images.
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